UPDATE: Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt

By: via Benzinga
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.